Key result
TnT-mutant HCM mice exhibit worse energy metabolism and phospholipid remodeling than MyHC-mutants, indicating allele-specific drivers.
Why the study?
It is unknown whether a common metabolic trait underlies the cardiac phenotype at the early disease stage in hypertrophic cardiomyopathy.
Hypertrophic cardiomyopathy (HCM) results from pathogenic variants in sarcomeric protein genes, that increase myocyte energy demand and lead to cardiac hypertrophy. But it is unknown whether a common metabolic trait underlies the cardiac phenotype at early disease stage. This study characterized two HCM mouse models (R92W-TnT, R403Q-MyHC) that demonstrate differences in mitochondrial function at early disease stage. Using a combination of cardiac phenotyping, transcriptomics, mass spectrometry-based metabolomics and computational modeling, we discovered allele-specific differences in cardiac structure/function and metabolic changes. TnT-mutant hearts had impaired energy substrate metabolism and increased phospholipid remodeling compared to MyHC-mutants. TnT-mutants showed increased incorporation of saturated fatty acid residues into ceramides, cardiolipin, and increased lipid peroxidation, that could underlie allele-specific differences in mitochondrial function and cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Vaniya et al. (2023) studied Hypertrophic cardiomyopathy. R92W-TnT mutation vs. R403Q-MyHC mutation was evaluated on Allele-specific differences in cardiac structure/function and metabolic changes. TnT-mutant HCM mouse models showed impaired energy substrate metabolism and increased phospholipid remodeling compared to MyHC-mutants, indicating allele-specific metabolic drivers of early disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: